Assessing the Effect of Patient Characteristics on Treatment Response in Primary Hyperhidrosis

February 4, 2020 updated by: Dee Anna Glaser, MD, St. Louis University

A Prospective Study Assessing the Effect of Patient Characteristics on Treatment Response in Hyperhidrosis

This study will describe the treatment of hyperhidrosis (excessive sweating) in clinical practice and explore the effect of patient characteristics on treatment response. This study will follow 200 people with hyperhidrosis over 18 months. Anyone with primary hyperhidrosis (excessive sweating not due to another medical condition) over the age of 12 may participate. Study participants will have multiple office visits during which they will asked to rate the severity of their sweat production in multiple areas (i.e. underarms, hands, feet), answer a questionnaire regarding their disease and treatment, and undergo a non-invasive measurement of sweat production called gravimetry. Gravimetry is performed by placing absorbent material in an area, such as the underarms, for a set amount of time and then measuring the amount of sweat collected. In between clinic visits, study participants will be contacted electronically to answer several questions regarding their disease and treatment.

Study Overview

Status

Completed

Conditions

Detailed Description

Subject Recruitment

Recruitment will take place at SLUCare Dermatology Des Peres Clinic. Patients with non-study related appointments with Dr. Glaser regarding the management of primary hyperhidrosis will be approached by a research member. Patients will be given ample time to review study design and have questions and concerns addressed. After inclusion and exclusion criteria, study purpose and design, signed consent (parent or guardian will sign if subject is a minor), assent (for minors only, not signed) and HIPAA release are attained, the patients will be enrolled in the study.

The investigators will be recruiting two types of patients for this study. (1) New patients being seen for evaluation for primary hyperhidrosis. These subjects will be presenting to the hyperhidrosis clinic for the first time. If enrolled, these subjects will have all data prospectively collected. (2) Established patients being seen for ongoing management of primary hyperhidrosis who have documented baseline gravimetric measurements (defined as measurements taken while the patient was undergoing no active therapies for primary hyperhidrosis). These subjects will be presenting to the hyperhidrosis clinic for continued care. If enrolled, these subjects will have some data collected retrospectively with the remainder collected prospectively (see below for details).

Withdrawal or Discontinuation

Subjects may withdraw from the study at any time. If a subject desires withdraw from the study, the subject will be give a reason for study withdraw which will be included in publication. If a subject misses a scheduled visit the subject will be contacted via phone to ask if the subject is withdrawing from the study or reschedule a visit.

Because the subjects are only undergoing gravimetry, a non invasive way of measuring sweat production, it is highly unlikely that there would be any reason to discontinue a subjects participation due to safety. However, if at any point the supervising provider feels that a patient is at risk of harm the subject may be withdrawn from the study. In this case, a reason would be recorded for publication purposes.

Screen Failures

For those that fail screening, all information collected prior to that time will be shredded and disposed of in confidentiality trash bins. Only a reason for failing to pass screening will be recorded for publication purposes.

Subject Visits

Subjects will be screened, sign consent (parent or guardian will sign if subject is a minor), review assent (only applicable to minors) HIPAA release, and enrolled at an initial visit. Patients will have a monthly electronic or telephone survey to fill out. Patients will be seen every 3 months in clinic until the patient has achieved treatment response and/or no treatment changes are required. 6 months after this visit, the patient will be seen in clinic again***. If the subject has a sustained treatment response and/or has no treatment change, the subject will exit the study. If these conditions are not met, then the subject will resume 3 month visits.

It is important to note that these visit will overlap with non-study related visits that occur as a part of management of the patient's disease. Disease management decisions, such as which therapy to prescribe, will occur independently of this study and will not be affected by study participation. All visits will occur within 18 months after the study begins. No further study encounters will occur after this time period regardless of treatment changes or response.

*** Subjects may choose to forgo this 6 months visit and complete it electronically or by telephone.

New Patient

Subject Visit 1, 1 hour:

The subject will first verify his or her name and contact information. After the subject agrees to study participation they will sign a consent (permission) and a release of health information. Consent will be signed by parent or guardian if the subject is a minor. If the subject is a minor assent will also be reviewed with the subject. Inclusion and exclusion criteria will be reviewed.

Through an interview with a research team member and chart review, the following data will be collected:

  • Basic demographics
  • Current treatments
  • Hyperhidrosis Disease Severity Scale score (a scale that rates how the subject feels sweating affects daily activities) for all sites:
  • Scalp
  • Face
  • Underarms
  • Inframammary
  • Chest
  • Back
  • Hands
  • Feet
  • Groin
  • Buttocks
  • Questionnaire regarding the subject's disease state (see attachment).

Patients will then undergo gravimetric measurements of all sites affected by hyperhidrosis as detailed in the attachment. Areas affected by HH will be defined by areas with an HDSS 3 or greater. For details on the gravimetry protocol, see attachment.

Subject Visits, follow-up, 30 minutes:

The following data will be collected through subject interview:

  • Current treatment
  • HDSS for all sites.
  • Questionnaire regarding the subject's disease state (see attachment).
  • Presence or absence of side effects

Patients will then undergo gravimetric measurements for sites with previous measurements. For detailed protocol see attachment.

Established Patient

Subject Visit 1, 1 hour:

The subject will first verify his or her name and contact information. After the subject agrees to study participation they will sign a consent (permission) and a release of health information. Consent will be signed by parent or guardian if the subject is a minor. If the subject is a minor assent will also be reviewed with the subject. Inclusion and exclusion criteria will be reviewed.

Through chart review, the following data will be collected:

  • Baseline (defined as data collected while the patient was not undergoing any treatment) HDSS score and gravimetric measurements for all sites
  • Number of treatment changes since initiating care
  • Basic demographics

Through an interview with the patient, the following information will be collected:

  • Current treatment
  • HDSS score for all sites
  • Questionnaire regarding the subject's disease state (see attachment).
  • Presence or absence side effects

Patients will then undergo gravimetric measurements for sites with previous gravimetric measurements.

Subject Visit, follow-up 30 minutes:

This will be the same as new patient follow up visits.

Subject Electronic/Telephone Survey: Monthly, 15 minutes

The following data will be collected through a phone or electronic interview between a research team member and the subject:

- Questionnaire regarding the subject's disease state (see attachment).

Study Type

Observational

Enrollment (Actual)

41

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Missouri
      • Saint Louis, Missouri, United States, 63131
        • Saint Louis University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Male or Females ≥ 12 with Primary Hyperhidrosis.

Description

Inclusion Criteria:

  1. Male or female of any race who has received the diagnosis of primary Hyperhidrosis at any site
  2. Patients receiving continued treatment of primary Hyperhidrosis with baseline gravimetrics (established patients only) performed at SLUCare Dermatology Des Peres clinic. Baseline gravimetrics are defined as measurements taken during times of no active disease interventions.

Exclusion Criteria:

  1. Received the following therapies at the site being evaluated prior to baseline gravimetrics:

    1. Botulinum toxin injections 6 months prior to baseline gravimetric data collection.
    2. Applied Aluminum chloride on day of baseline gravimetric data
    3. Ongoing iontophoresis therapy at time of baseline gravimetric data
    4. Oral systemic anticholinergics 4 weeks prior to baseline gravimetric data
    5. Received surgical intervention, suction and curettage, microwave thermolysis, or ultrasound therapy prior to baseline gravimetrics.
  2. Patient has received diagnosis of secondary hyperhidrosis (i.e hyperhidrosis due to an underlying medical condition such as hyperthyroidism)
  3. Younger than 12 years of age.
  4. Does not desire study participation or is unable to consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Patients with Hyperhidrosis
Subjects with Primary Hyperhidrosis will be followed in this study. Because this study is observational, there will be no intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weeks till treatment response
Time Frame: 18 months
We will measure the weeks required to reach treatment response defined as HDSS of 1 or 2.
18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of treatment changes
Time Frame: 18 months
We will quantify the number of failed treatment prior to treatment response.
18 months
Number of treatments at the time of treatment response.
Time Frame: 18 months
We will quantify the number of treatments a subject is currently using at the time of treatment response.
18 months
Percent reduction in gravimetric sweat measurements
Time Frame: 18 months
We will quantify the percent reduction in gravimetric sweat measurements from initial visit compared to after treatment response is achieved.
18 months
Disease impact
Time Frame: 18 months
We will track the disease impact through questionnaire responses throughout the study.
18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

St. Louis University

Investigators

  • Principal Investigator: Dee A Glaser, MD, St. Louis University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 20, 2018

Primary Completion (Actual)

August 12, 2019

Study Completion (Actual)

December 1, 2019

Study Registration Dates

First Submitted

October 1, 2018

First Submitted That Met QC Criteria

October 1, 2018

First Posted (Actual)

October 3, 2018

Study Record Updates

Last Update Posted (Actual)

February 5, 2020

Last Update Submitted That Met QC Criteria

February 4, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 29446

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperhidrosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe